deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03115801

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies

Sponsor: Weill Medical College of Cornell University

Conditions Metastatic Renal Cell Carcinoma Metastatic Urothelial Carcinoma
Interventions Atezolizumab Nivolumab Pembrolizumab Radiation & immunotherapy
Updated 14 times since 2017 Last updated: Aug 26, 2021 Started: Nov 30, 2016 Primary completion: Oct 13, 2020 Completion: Oct 13, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of accrual

Other terminated trials from Weill Medical College of Cornell University

See all terminations from Weill Medical College of Cornell University

Other Metastatic Renal Cell Carcinoma trials with similar outcome

Browse all Metastatic Renal Cell Carcinoma trials

A PHASE2 clinical study on Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Weill Medical College of Cornell University and has accumulated 14 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2019 · 13 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Sep 2018 — Oct 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations